Valneva SE

NASDAQ:VALN

Biotechnology

Healthcare
$5.34 +0.19%

+$0.01 today

Market cap
$507.98M
Beta
1.40
P/E (TTM)
-2.9
EPS (TTM)
-$0.80
52W Low $5.06High $12.25

Volume 0.00M

Average 0.09M

VALN Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Valneva SENASDAQ: VALN

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses remains negative

Q1 FY2026 other income / expenses was -€7.55M, compared with -€1.8M a year earlier. Trailing-twelve-month other income / expenses was -€38.24M.

Context

  • Other income / expenses amounted to 18.6% of revenue in FY2025, up 4.0 pp from a year earlier.
  • Other income / expenses grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other income / expenses holds near -€7.55M or moves back toward the trailing-twelve-month quarterly average of -€9.56M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-€7.55M+67.7% QoQ
Last fiscal yearDec 2025
-€32.49M-30.9% YoY
LTMMar 2026
-€38.24M-120.8% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-320.1%——
1 year-30.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

EUR · from the income statement

Latest · FY2025
(32.49M) EUR
Year-over-year change
-30.9%

Other Income / Expenses vs competitors

How VALN compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -120.8% is the 6th highest of 8, against a peer median of -71.4%.
  • Other income / expenses amounts to 24.5% of revenue for VALN, versus a peer median of 23.2%.
VALN Competitors
Other Income / Expenses for VALN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRNAModerna, Inc.LTM Sep 2026$201M USD-35.2%+25.4%8.0%
PCVXVaxcyte, Inc.LTM Jun 2026$101.03M USD-37.5%+161.6%—
VIRVir Biotechnology, Inc.LTM Mar 2026$19.31M USD-71.4%—29.5%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$10.54M USD-22.0%—23.2%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026-$1.21M USD-112.8%——
NVAXNovavax, Inc.LTM Mar 2026-$19.43M USD-125.2%—3.3%
VALNValneva SELTM Mar 2026-€38.24M EUR-120.8%—24.5%
IBRXImmunityBio, Inc.LTM Sep 2026-$835.68M USD-850.2%—457.7%
Peer median (excluding VALN) —-71.4%+93.5%23.2%

Competitors are the stored peer set for VALN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue348.09M361.3M153.71M169.58M174.66M
Cost of Revenue187.92M324.44M100.88M98.54M107.14M
Gross Profit160.17M36.86M52.84M71.04M67.52M
Gross Margin46.0%10.2%34.4%41.9%38.7%
Research & Development173.28M104.92M59.89M74.14M85.3M
Selling, General & Admin71.25M57.58M96.55M95.11M74.68M
Operating Expenses221.56M150.31M134.92M57.71M149.15M
Depreciation & Amortization14.28M21.04M17.58M19.59M21.75M
EBITDA(38.74M)(104.73M)(57.72M)32.08M(50.47M)
EBITDA Margin-11.1%-29.0%-37.6%18.9%-28.9%
Operating Income(61.39M)(113.44M)(82.09M)13.33M(81.63M)
Operating Margin-17.6%-31.4%-53.4%7.9%-46.7%
Interest Income249K260K1.21M2.36M1.8M
Interest Expense16.96M19.05M23.33M23.98M41.9M
Other Income / Expenses(8.59M)(31.37M)(16.54M)(24.82M)(32.49M)
Income Before Tax(69.98M)(144.82M)(98.63M)(11.49M)(114.12M)
Pre-Tax Margin-20.1%-40.1%-64.2%-6.8%-65.3%
Income Tax Expense3.45M(1.54M)2.8M761K1.07M
Net Income(73.43M)(143.28M)(101.43M)(12.25M)(115.19M)
Net Margin-21.1%-39.7%-66.0%-7.2%-66.0%
EPS (Basic)(1.50)(2.48)(1.46)(0.17)(1.32)
EPS (Diluted)(1.50)(2.48)(1.46)(0.17)(1.32)
Weighted Avg Shares48.81M57.74M69.47M70.26M84.09M
Weighted Avg Shares (Diluted)48.81M57.74M69.31M70.26M84.09M

Valneva SE

NASDAQ:VALN

Intrinsic Alpha fair value

Locked

Current Price

$5.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.